Who
William Grossman
Interim Chief Medical Officer
Company insider
Files Form 4 as: Interim Chief Medical Officer, enGene Therapeutics; Director, Day One Biopharmaceuticals; Chief Medical Officer, Arcus Biosciences; Sr. VP, Chief Medical Officer, Bellicum Pharmaceuticals.
In numbers
- Trades disclosed
- 44
- Buys
- 4
- Sells
- 5
- Bought
- $27K
- Sold
- $439K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 5 Feb 2018
- Last trade
- 22 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Sep 2026filed 24 Sep 2026 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K5,102 at $1.97 | filing |
| 22 Sep 2026filed 24 Sep 2026 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K5,102 at $1.97 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —66,660 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —32,335 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —66,660 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,335 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,500 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 23 Apr 2026filed 23 Apr 2026 | Day One Biopharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —66,660 at $0.00 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —66,660 at $0.00 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,335 at $0.00 | filing |
| 6 Nov 2025filed 7 Nov 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —32,335 at $0.00 | filing |
| 8 Jul 2025filed 10 Jul 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | Day One Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.